結核検査の世界市場-2022-2029

市場力学

結核検査市場は、結核および多剤耐性結核の負担増、政府の取り組みの増加、新興市場における認知度の上昇によって牽引されています。

結核の負担増が市場成長の原動力になると予想されます。

コロナウイルス感染者の増加、結核患者数の増加が市場を牽引します。世界保健機関（WHO）によると、2020年には世界で推定1000万人が結核で倒れ、男性560万人、女性330万人、子ども110万人となり、これは世界の結核死亡者数の半分以上となります。市場成長の促進要因としては、結核および多剤耐性結核の負担増、研究開発投資の増加、製品パイプラインの充実、新興市場における政府の取り組み強化などが挙げられます。結核診断薬の状況は、過去10年間で劇的に変化しています。さらに、WHOの世界結核プログラムに対応して、技術の評価と政策の策定に使用される体系的かつ動的なプロセスを実施し、市場の成長を促進しています。

また、結核の有病率は年々増加しており、診断検査（X線検査など）を選択するよう人々に影響を与える政府の啓発プログラムの数とともに、予測期間中に市場を牽引することが期待されます。また、結核の基礎研究に拍車をかけ、パイプラインの診断薬の市場承認を加速させる機会が市場に存在することから、同市場は成長を遂げると予想されます。さらに、ゲノミクスとプロテオミクスの技術開発は、診断プロバイダーが結核診断薬の製品開発を促進するために活用することが可能です。

高負担地域でのスクリーニング率の向上、診断薬の低価格化、高度な調査手法、迅速な臨床判断、死亡率の低下などが開発の焦点となっています。予防・治療診断率の向上は、これらの取り組みの成果です。このため、診断検査に対する需要が高まり、結核診断薬市場が活性化しました。さらに、政府や独立した医療機関は、この感染症の蔓延を抑制するための取り組みを行っています。診断の重要性に関する意識向上は、スクリーニングや診断率の向上に不可欠であり、結核診断薬市場のさらなる繁栄に寄与しています。このような要因が、予測期間中の市場成長を後押ししています。例えば、インドのRevised National Tuberculosis Control Program（RNTCP）は、結核スクリーニングの実施と、無料診断・治療プログラムによる治療へのアクセス向上に重点を置いています。また、このプログラムによる官民パートナーシップが、診断率を押し上げています。

60歳以上の人口は感染症にかかりやすいため、結核診断薬市場のターゲットとなる人口です。その結果、老年人口層の増加が市場の成長を促進しています。

結核治療薬による薬剤耐性は、市場成長の妨げになると予想されます。

しかし、結核の薬剤耐性は医療従事者にとって主要な懸念事項の1つです。間違った薬剤レジメンや不適切な投与形態による不適切な治療が、治療中の結核患者の薬剤耐性につながり、市場の成長を抑制しているからです。

産業分析

結核検査の世界市場は、ポーターのファイブフォース、規制分析、サプライチェーン分析、価格分析、製品イノベーション、アンメットニーズなど、様々な業界要因に基づく市場の詳細な分析を提供しています。

結核検査の世界市場レポートでは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 結核検査の世界市場の調査手法と範囲

• 調査手法
• 調査目的・調査範囲

第2章 結核検査の世界市場-市場の定義と概要

第3章 結核検査の世界市場-エグゼクティブサマリー

• 検査タイプ別市場内訳
• エンドユーザー別市場内訳
• 地域別市場内訳

第4章 結核検査の世界市場力学

• 市場影響要因
  • 促進要因
    • 結核と多剤耐性結核の負担増
    • 新興市場における政府の取り組みと意識の高まり
  • 抑制要因
    • 結核診断にかかる高いコスト
    • 結核治療薬に対する耐性
• 影響分析
• 機会

第5章 結核検査の世界市場-産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制分析
• 価格設定分析
• 製品分析
• 産業バリューチェーン分析

第6章 結核検査の世界市場-検査タイプ別

• 核酸ミオスタリング
• サイトカイン検出アッセイ
• 潜伏感染の検出
• 培養ミオイド検査
• 薬剤感受性ミオスタチング
• その他

第7章 結核検査の世界市場- エンドユーザー別

• 病院の検査室
• 研究機関
• 診療所検査室
• 診断センター

第8章 結核検査の世界市場- 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第9章 結核検査の世界市場の競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A（合併・買収）分析

第10章 結核検査の世界市場企業プロファイル

• Thermo Fisher Scientific, Inc.
  • 企業の概要
  • 製品ポートフォリオと説明
  • 主な発展状況
  • 財務概要
• Hologic Corporation
• Abbott Laboratories
• Alere, Inc.
• Lupin Pharmaceuticals, Inc.
• Becton, Dickinson and Company
• F. Hoffmann-La Roche AG
• bioMerieux SA
• Sanofi.
• Cepheid
• List is not exhaustive

第11章 結核検査の世界市場- 重要考察

第12章 結核検査の世界市場-DataM

Market Overview

The Tuberculosis Testing Market size was valued at US$ 1,337.10 million in 2021 and is estimated to reach US$ 2058.0 million by 2029, growing at a CAGR of 6.0% during the forecast period (2022-2029).

Tuberculosis (TB) is a communicable disease that is a major cause of ill health, one of the top 10 causes of death worldwide, and the leading cause of death from a single infectious agent. It is caused by the bacillus Mycobacterium tuberculosis, which is spread when sick people with TB expel bacteria into the air, for example, by coughing. It typically affects the lungs (pulmonary TB) but can also affect other sites. About a quarter of the world's population is infected with M. tuberculosis and thus at risk of developing TB disease. Tuberculosis testing can be defined as the most commonly used diagnostic tool for tuberculosis. With a timely diagnosis and treatment with first-line antibiotics for 6 months, most people who develop TB can be cured, and onward transmission of infection curtailed. The number of TB cases occurring each year can also be driven down by reducing the prevalence of health-related risk factors for TB providing preventive treatment to people.

Market Dynamics

The tuberculosis testing market is driven by the increasing burden of tuberculosis and multidrug-resistant tuberculosis, increasing government initiatives and rising awareness in the emerging market.

Increasing burden of tuberculosis are expected to drive market growth.

The market is driven by the increasing number of coronavirus cases, increasing the number of tuberculosis patients. According to the World Health Organization (WHO), in 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide, 5.6 million men, 3.3 million women and 1.1 million children, which is more than half of global TB deaths. Factors propelling the market's growth include the increasing burden of tuberculosis and multidrug-resistant tuberculosis, increasing R&D investments, intensive product pipelines, and increasing government initiatives in the emerging markets. The landscape of TB diagnostics has changed dramatically during the past ten years. Moreover, in response to the WHO Global TB program, it has implemented a systematic and dynamic process used to evaluate technologies and develop policies, which has enhanced the market's growth.

The prevalence rate of tuberculosis is also increasing every year, along with the number of government awareness programs that influence people to opt for diagnostic tests (like radiographic tests), which are expected to drive the market during the forecast period. The market is also expected to witness growth as there is an opportunity for players in the market to accelerate their pipeline diagnostic products' market approval by spurring the fundamental research in TB. Additionally, technological developments in genomics and proteomics can be leveraged by diagnostic providers to hasten product development in TB diagnostics.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the results of these initiatives. This has led to a subsequent upsurge in demand for diagnostic tests and the TB diagnostics market. Furthermore, the government and independent healthcare organizations have undertaken initiatives to control this infectious disease's proliferation. Creating awareness about the importance of diagnosis is vital in increasing the screening and diagnosis rates, further helping the TB diagnostics market flourish. This factor is driving the growth of the market in the forecast period. For instance, the Revised National Tuberculosis Control Program (RNTCP) in India focuses on performing TB screening and providing greater access to treatment through free diagnosis & treatment programs. Besides, private-public partnerships under this program are boosting the diagnosis rate.

Population above the age of 60 is the target population for the TB diagnostics market as this demographic is susceptible to infectious diseases. The growing geriatric population base, as a result, is driving the growth of the market.

Drug resistance with tuberculosis drugs is expected to hamper the market growth.

However, drug resistance in tuberculosis is one of the primary concerns for healthcare professionals as improper treatment due to wrong drug regimens and incorrect dosage forms lead to drug resistance in TB patients undergoing treatment, restraining the market's growth.

Industry Analysis

The global tuberculosis testing market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs.

Segment Analysis

Test type segment is expected to hold the largest market share in global Tuberculosis Testing market

The global tuberculosis testing market is segmented on test type by Cytokine Detection Assay, Nuclеic Acid Tеsting, Detection of Latent Infection, Culturе Basеd Tеsts, Drug Suscеptibility Tеsting, and Othеrs. The Nuclеic Acid Tеsting segment held the largest market share due to its use as diagnostic tools for tuberculosis (TB) for many years, and which continue to be used. There are substantial advancements in the diagnosis of TB. Moreover, these tests have been commercially available in the United States for over two decades that offer better accuracy than other microscopy tests and even provide greater speed than culture-based tests. A nucleic acid test for tuberculosis (TB) is a molecular test used to detect the DNA (deoxyribonucleic acid) of Mycobacterium tuberculosis complex (MTBC) in sputum or other respiratory samples. Because the amount of DNA in a sample is minimal, NAA testing includes a step that amplifies (or copies) the genetic material. Polymerase Chain Reaction (PCR) is a common form of nucleic acid test used in laboratory diagnosis. Drug Suscеptibility Tеsting is expected to have positive market growth because they are cost-efficient and easy-to-perform. The high burden regions rely on these methodologies due to their financial and technical incapability to incorporate advanced technologies, thus contributing to its growth.

A Cytokine Detection Assay is usually employed to check for the specific cytokines being secreted. This is more a function of biochemistry research rather than a specific test for body functions. Cytokines and their receptors are under a great deal of research because of their role in disease control. It is worth noting that many cytokines have an opposing and sometimes complementary effect on each other; thereby, modulating the immune response's severity. Cytokine assays are used to identify which cytokines and their deficiencies are responsible for the cause of some autoimmune diseases.

A Detection of Latent Infection The goal of testing for LTBI is to identify individuals at increased risk for developing tuberculosis (TB) and, therefore, who would benefit from treatment of latent TB infection. Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive. This factor would drive the growth of the market in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global tuberculosis testing market

By region, the Tuberculosis Testing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Asia-Pacific dominated the global tuberculosis testing market and is expected to grow at the highest CAGR during the forecast period. The growth of the market in the region is attributed to tuberculosis's high burden and the rapid proliferation of this disease. The increasing prevalence of TB in Japan helps in the TB diagnostics market's growth. The high prevalence of TB creates an urgent demand for effective and quick diagnosis of the disease. Besides, in countries such as India, according to the recent budget announcement, the Government of India aims to eliminate tuberculosis by 2025, which is expected to act as one of the major factors for the growth of the Asia-Pacific market forecast period.

Infectious and Endemic Disease Control in China, RNTCP in India, and the National TB program in Afghanistan are the few programs planned by local healthcare agencies to contain the incidence and ensure equitable access to diagnosis. As per the WHO, countries such as India, China, Afghanistan, and Indonesia are priority regions for controlling this communicable disease.

Competitive Landscape

The global tuberculosis testing market is highly competitive, with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Thermo Fisher Scientific, Inc., Hologic Corporation, Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, bioMerieux SA, Sanofi, Cepheid, Hain Lifescience GmbH, are the leading market players with significant market share.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

The Abbott RealTime MTB assay is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of MTB complex DNA in smear positive or smear negative specimen of sputum or bronchial alveolar lavage and N-acetyl-L-cysteine (NALC)-prepared sediments prepared from sputum and broncial alveolar lavage collected from individuals suspected of having tuberculosis (TB).

The global tuberculosis testing market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Global Tuberculosis Testing Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Tuberculosis Testing Market - Market Definition and Overview

3. Global Tuberculosis Testing Market- Executive Summary

• 3.1. Market Snippet by Test Type
• 3.2. Market Snippet by End User
• 3.3. Market Snippet by Region

4. Global Tuberculosis Testing Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing burden of tuberculosis and multidrug-resistant Tuberculosis
    • 4.1.1.2. Increasing government initiatives and rising awareness in the emerging Market
  • 4.1.2. Restraints
    • 4.1.2.1. High costs associated with tuberculosis diagnostics
    • 4.1.2.2. Resistance to the TB medicines
• 4.2. Impact Analysis
• 4.3. Opportunity

5. Global Tuberculosis Testing Market - Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis
• 5.4. Pricing Analysis
• 5.5. Product Analysis
• 5.6. Industry Value Chain Analysis

6. Global Tuberculosis Testing Market - By Test Type

• 6.1. Introduction
• 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
• 6.3. Market Attractiveness Index, By Test Type
  • 6.3.1. Nuclеic Acid Tеsting*
    • 6.3.1.1. Introduction
    • 6.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
  • 6.3.2. Cytokine Detection Assay
  • 6.3.3. Detection of Latent Infection
  • 6.3.4. Culturе Basеd Tеsts
  • 6.3.5. Drug Suscеptibility Tеsting
  • 6.3.6. Others

7. Global Tuberculosis Testing Market - By End-User

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
• 7.3. Market Attractiveness Index, By End User
  • 7.3.1. Hospital laboratories*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, USD Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2027
  • 7.3.2. Research laboratories
  • 7.3.3. Clinics laboratories
  • 7.3.4. Diagnostic center

8. Global Tuberculosis Testing Market - By Region

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
• 8.3. Market Attractiveness Index, By Region
• 8.4. North America*
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. U.S.
    • 8.4.5.2. Canada
    • 8.4.5.3. Mexico
• 8.5. Europe
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. Germany
    • 8.5.5.2. U.K.
    • 8.5.5.3. France
    • 8.5.5.4. Rest of Europe
• 8.6. South America
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.6.5.1. Brazil
    • 8.6.5.2. Argentina
    • 8.6.5.3. Rest of South America
• 8.7. Asia Pacific
  • 8.7.1. Introduction
  • 8.7.2. Key Region-Specific Dynamics
  • 8.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.7.5.1. China
    • 8.7.5.2. India
    • 8.7.5.3. Japan
    • 8.7.5.4. Australia
    • 8.7.5.5. Rest of Asia Pacific
• 8.8. The Middle East and Africa
  • 8.8.1. Introduction
  • 8.8.2. Key Region-Specific Dynamics
  • 8.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

9. Global Tuberculosis Testing Market Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Global Tuberculosis Testing Market Company Profiles

• 10.1. Thermo Fisher Scientific, Inc. *
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Key Developments
  • 10.1.4. Financial Overview
• 10.2. Hologic Corporation
• 10.3. Abbott Laboratories
• 10.4. Alere, Inc.
• 10.5. Lupin Pharmaceuticals, Inc.
• 10.6. Becton, Dickinson and Company
• 10.7. F. Hoffmann-La Roche AG
• 10.8. bioMerieux SA
• 10.9. Sanofi.
• 10.10. Cepheid
• List is not exhaustive

11. Global Tuberculosis Testing Market - Premium Insights

12. Global Tuberculosis Testing Market - DataM

• 12.1. Appendix
• 12.2. About Us and Services
• 12.3. Contact Us